Artrya Limited (ASX:AYA)
Australia flag Australia · Delayed Price · Currency is AUD
2.840
-0.220 (-7.19%)
Nov 17, 2026, 11:34 AM AEDT
← View all transcripts

Bell Potter Healthcare Conference

Nov 17, 2026

Summary

Salix combines cardiac CT anatomy, plaque and flow analysis in one workflow; Tanner reported 50% better workflow efficiency, while customer CCTA volumes are growing 20%–25%. Five customers are signed, and near-term focus includes rollout, plaque reimbursement adoption and the SCF submission.

We are pleased to welcome John Konstantopoulos, Co-Founder and CEO of Artrya, and Clayton Hatch, the recently appointed CFO, to discuss the business with us today. Artrya is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyzes coronary CT scans to identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya has an FDA approval for two of its three modules and is working on the submission for the FFRCT module. There are now five customers signed up in this early commercialization phase, including the first inbound non-SAPPHIRE customer last week, in HonorHealth. Notably, Artrya recently achieved an important milestone with ASX 300 index inclusion, opening the company up to a wider pool of investors. Welcome, John and Clayton. How are you today? Hey, Marty. Good to see you. Good, thanks. Yeah. Thanks. You too, Marty. We'll have a bit of a discussion, lasting 25 minutes, and we'll kick it off with, a lot has happened recently since we last spoke at the conference last year. I think a good place to start is to remind the audience of the core fundamentals of the Salix platform. What problem is Salix trying to solve? Sure. Yeah, Marty, I think it's a good point to start with the problem we're actually solving. Cardiac CT is really becoming an important tool for diagnosing coronary artery disease, especially within hospitals that have more and more patients coming into the hospital system with chest pain and symptoms. The problem is that cardiologists are spending a lot of time reviewing and reporting scans, often using multiple software solutions to not only look at the CT scan, but also look at the plaque that causes heart attacks, and then the validation of that plaque, whether it's going to be blood flow limiting or not. As the demand has been growing, the capacity of these doctors is becoming less and less. So they're under severe pressure. They're limited amount in the number of patients they're able to see, and it's really impacting the economics of the hospital system to be able to effectively deliver profitable services. I think the most important thing is that patients aren't getting seen fast enough as well. We're seeing a lot of big backlogs in the U.S. at the moment, some four to eight weeks long. That's really what Salix is there to address. It's an AI-powered platform that brings an entire cardiac CT reporting workflow, a single solution that assesses a cardiac CT in real time and at the point of care, and it allows the doctor, in that real-time manner, not only become a lot more efficient in their reporting and get more patients through the system a lot faster, but also treat the patients a lot faster as well by allowing them to see the plaque that causes the heart attacks in real time and allowing them to validate whether that plaque is blood flow limiting or not in real time as well. If I can summarize that into probably three major points is, the first is clinical efficiency. The platform tackles that. It allows them to focus on one single platform and increase their throughput. It improves hospital economics, just because of them getting more patients through. But the most important piece is much better clinical decisions for the patients as well. Right. Excellent. Thank you very much for that. I think there are six other competitors in your sector, and I was just wondering, noting what you have just said, what distinguishes Salix from them? Marty, we will tag-team this, so I will hand that one over to Clayton, just we will tag-team on these questions, yeah? Yeah, sure. That is fine. Yeah, I mean, six in the space, I think we really only see one or two competitively, or we replace. Obviously, HeartFlow is the main one we are replacing at the moment. But in saying that, they all do something slightly different. They are all point-of-care solutions, as opposed to a platform, as John mentioned, the work we do with the Salix Coronary Anatomy. I think that is the big distinguishing piece that comes out of what we do compared to the competitors. If you like, and that we also have a competitor in someone like the cardio PACS, so TeraRecon or a Philips or a GE, that is what we are replacing with the actual platform. And then for like, flow, we will be competing against HeartFlow, and then for plaque flow, Cleerly, Elucid. There are competitors in different areas, but no one that does everything that we do within our platform. Right. In the case of HonorHealth and Huntsville, who are you replacing there? Yeah, so both of them. Sorry, I'm going to rephrase that. With HonorHealth, we're replacing TeraRecon and HeartFlow. In HonorHealth, it's Canon Vitrea and HeartFlow. HeartFlow was actually replaced a little while ago, not by us. They just removed them. But effectively, it's Canon Vitrea as the reporting platform we're replacing. Right. Right, I see. That's really exciting for the company then. At the recent quarterly update, Northeast Georgia Health System and Cone had not yet completed onboarding all of their sites. Where does that stand now with only five weeks to Christmas? Yeah, I'll take that one. Look, we're working very closely with Northeast Georgia at the moment, so they're fully live in their Gainesville site. They've got two major reporting sites, Gainesville and Braselton here in the U.S. Gainesville is already live with their doctors reporting. Then we're working on onboarding the clinicians from Braselton at the moment. From their perspective, they wanted to stage it. Once we integrated to the PACS, we start receiving all the CCTA scans. They only wanted to do the first major hospital center, Gainesville first, and then go to Braselton, the second hospital system afterwards. Cone, we're working with them at the moment around an onboarding process. Partly, that was delayed because of their acquisition by Kaiser, which, in the grand scheme of things, is a real positive for us because Cone sees the huge benefit in using the platform, and it's a real good entry point into a big animal like Kaiser in the future. We're working with Cone at the moment around that process. I guess it's premature to be having any discussions with Kaiser at this point. Is that correct? About 100%, yeah. Cone, our priority is get them live, get them using it, show efficiency, and then use those efficiency benefits to sell up into the bigger mothership. Right. Okay. Where does Tanner Health now sit on the adoption curve of plaque analysis, and when do you envisage it will reach that 70% benchmark that the company has set for itself? Yeah. It's not so much we've set the benchmark, it's industry standard. HeartFlow spoke about plaque last week on their quarterly calls as well. Oh, have we lost Clayton? I can't hear Clayton. Yeah. I think he's frozen. I'll carry on what he was saying. Clayton, are you there? Yep. Yeah. We lost you there. Do you want to just go back again? Yeah, sorry about that. I am not sure why it is unstable. The plaque only became Category I code at the start of this year, so it is starting to build up to those plaque numbers. As HeartFlow mentioned on their quarterlies last week, that is an industry standard around 60%-65%. It is not something that we have set, but it is starting to build up to those numbers. We think as we get further adoption with additional customers, we will get those plaque numbers up around that 60% mark. Right. What productivity improvements is Tanner Health exhibiting since adopting Salix? Yeah. The latest numbers we have got is that, and this is from them, they have said that they have seen a 50% improvement in workflow efficiency with regards to their cardiologists. So much so that they are not reporting in the evening anymore, which is a If you think of not only is throughput an issue, but cognitive burden for doctors is becoming a real issue as well. So they are having to do more with a lot less time and a lot less tools. Giving them 50% of reporting time back has been a major benefit for Tanner, and they are now starting to report within their rounds. Right. Okay. How much more CCTA volume do you think that customers expect to generate because of using the platform and a year in? Is Tanner Health exhibiting more than 50% volume growth as a result of that 50% productivity saving, or is it around about that same mark? Yeah. I think they're probably getting their hours back. Yes, so rather than just seeing a 50% throughput on CCTA volume, they can actually have a night, and they're not reporting at night, as John mentioned. We're not seeing that number, but it becomes a lot easier for them to report their normal volume plus a certain percentage. What we are seeing through Tanner and even some of the other customers is their CCTA volumes are growing much higher than industry standard, more around the 20%-25% mark. Using something like the Salix platform allows them to obviously do that in a more efficient time and get those hours back. Right. I think the answer will be we are seeing a lot more the volume grow. It's not quite to that extent, but yeah, they're getting some hours back. Okay, that's interesting. It's a nice segue into the next question, that CCTA utilization overall seems to be going gangbusters from what we read in the trade press, with usage now up to around 4 million scans overall, growing at strong double digits, as you alluded to. I noted in the Huntsville investor call, there was a reference to overall testing volumes that were multiples of CCTA scanning, and obviously belonging to other modalities. Do you think hospitals will happily switch over more of that volume into CCTA, and what would be the drivers of such a move? Yeah, look, we're really seeing that, as you rightly said, the 25%-35% growth rates from Cone and Huntsville. We've seen the Brigham, this came out in the Cardiovascular Business News recently, where they said in the past they were doing 30 scans a day. They're doing 80 to 100 scans a day at the moment, obviously across all their cardiologists. which is significant growth. The reason we see that is because, one, the guidelines have now made CCTA as the primary test for anybody with chest pain coming to the hospital system. It's shifted away from invasive tests like nuclear imaging, SPECT, exercise stress treadmill tests, the ones that are very inconclusive on whether it's coronary artery disease or not. The reimbursement has definitely driven that. CCTA reimbursement's increasing, the nuclear testing and SPECT reimbursement is coming down. Then you have the plaque reimbursement of close to AUD 1,000, and the blood flow analysis, let's say close to AUD 1,000 as well, which is really driving that adoption. The main thing is just, it's also better patient care. You can really see the coronary arteries well. You can make a better informed decision for the patient. You can also do it faster. Instead of waiting 45 minutes for a SPECT test, you can do this in five to 10 minutes, which allows you to get patients through the system as well. Switching software programs is difficult to achieve. People are attached to something, even if it's suboptimal. There's inertia with adopting something new. Even if the data shows it's better for them, that's the nature of human beings. Why do you think hospital systems en masse will actually switch and go through that transition phase? When we say en masse, we mean over time. Yes. Yeah, because, yeah. Yeah. So over time, I think, as John mentioned, the platform and everything that we run through the system will make it easier to swap out two or three different systems into one. So not having, like I said, TeraRecon, HeartFlow, and possibly a Cleerly for plaque, you can do that all under one. It is more efficient. If you can make the doctors more efficient and save them money or increase their revenue that they are going to do in the biggest department, being the cardiology department, if you can make them more efficient and get margin increase for the cardiology department, it lifts the whole hospital group up. Thirdly, as John mentioned, it is better patient care to be able to use something like this as opposed to current invasive surgery, invasive systems. So, I think it is something that they will start using. It is new. It is about 10%-11% penetrated in non-invasive sort of work under the flow and plaque sort of work. So, I think it is something that they will start to adopt, and as you do, having the platform will make it a lot easier to keep them longer term. Can you tell us about the sort of training program and support, and how long that kind of integration takes, either at a single-site hospital or across the whole system? Look, I think that varies from hospital to hospital, but in essence, from what we do is, we train the technologists to make sure that the image acquisition is of high quality. That's just a standard thing that all of us do. We then also make sure we train the doctors on the usage of Salix, and one of the things we've learnt fairly early is that instead of training them on the software itself, train them on cases. So they like case studies and use cases, so we've been very focused on making sure that we're getting their scans in from their patients, and we train them on those scans. Then we get them to work through their workflow using Salix, and we walk with them along that journey so they get very comfortable with that, and that goes fairly quickly. Then from there, once they go live, we've got a hypercare period that usually lasts about 60, excuse me, 60 days. In that hypercare period, same thing. We shadow some of the cardiologists over a period of time and just make sure that they're using Salix to the best and its maximum efficiency to get the efficiency that they can get from it. That all happens while the integration is happening. Excuse me. That all happens while integration is going on. So it all runs in parallel. Right. Okay. So, in a system like Huntsville or HonorHealth, you think the total integration time from contract to first revenue should be three to four months? It varies quite a lot. It depends on every group. It varies. I think what we've seen is that once we know IT is involved, then we get a clear gauge on how much we've got to drag them over the line by the scruff of the neck, and how much it's going to be a bottleneck with them. Or sorry, when I say bottleneck, how much it's going to be, we've got to wait on their timelines. It just varies. We've seen some very fast, some take a little longer, and we'll know that once we get engaged with their IT teams. We have a question from the audience which refers to, I guess, the financial aspect of it. The question is, are hospitals and cardiology providers willing to pay for Salix at scale rather than simply trialing the technology? Yeah. I mean, trialing it, they're going to be using something, so yes, I do think they will be doing it en masse because, one, they get reimbursed, and second of all, it's a better outcome for them and makes them more efficient, so it lifts their margins. Given that you're sort of 10, 11 months in since reimbursement kicked in, or Category I code reimbursement, what do you think are the main bottlenecks you've experienced, and how have you addressed them, and do you see those bottlenecks or other bottlenecks appearing in the near term? I'll go first, and then Clayton, you've seen a few as well. IT is always going to be a limitation factor with any hospital system in the U.S. They have a lot of control with regards to software solutions and timing and when things go in. I won't really say that's a bottleneck as such. It's just a process we've got to deal with. Every hospital system has that process, and some are faster, some are slower. So that's the one thing we've just got to be aware of. If we knew that they were 100% going to be working on our timelines, we could integrate really fast. We're just depending on their capacity. So that's one thing. The other one is, because our turnaround time in real time, effectively eight minutes in healthcare, we initially saw that reimbursement or pre-authorization took longer because we were a lot faster than what a lot of the other solutions are in the field. We've worked very closely at bringing in quite a unique and novel pre-authorization or streamlined reimbursement process that allows them to get to that pre-authorization and get to that reimbursement a lot faster and match our turnaround time, which is quite unique and is a big value add to our customers because it means they get to money a lot faster as well. So that's one bottleneck that we've solved. Beyond that, I mean, just general things. I mean, obviously, every time you talk to a doctor, they like their own way of doing things. Everybody wants a feature, and we just manage those over time. That's just been in market. I can't think of anything else, Clayton. Can you? No, I think the plaque analysis is a new form of therapy. This is new to a lot of cardiologists. There are some that are more mature, and I think with Cone and Huntsville, we have people like that, and others that are more early on the early stage in terms of plaque analysis. Having them up and running whilst reimbursement does take time, I think we're at about 82% lives covered now for plaque, so that's positive. I think once it gets to 90%, 92%, that'll be almost automatic for the hospitals to run and start clicking on plaque almost without worrying too much, because that's part of a normal cycle for the revenue management team to take care of. I think plaque will get there. As you mentioned, it's about 10 months. It'll probably take about 16-18 months, similar to what it took for flow to get up to the levels that we thought, or that the market or industry thought it would be. Yeah, I think we're getting there. So, 82% lives covered. I think at the last quarterly update, I think that was at 78%, so it seems like it's moving quite rapidly now. Yes, that's right. It'll continue to do so. I mean, 10 months in, that's pretty normal. I think they'll all get there, all the insurers. They might do their policy wording and changes to their policies once a year, and maybe we'll see in the new year that they'll start picking up. Like I said, once they get to sort of that 92%, most hospital groups go, "That's normal sort of levels." It's up to our revenue management team to look after that. They're pretty confident then on clicking it. Obviously, the work we've done with the pre-authorization helps them get there and get comfort a lot quicker. But it's more of a timing thing that this will be something that eventually will be normal path, of course. Right. Now, Clayton Hatch, here's a question for you, coming from your experience with Pro Medicus. What did you learn about dealing with U.S. hospitals, contracting, or any other facet of the whole relationship? Yeah, it takes a lot of time. Anything that thinks that you can go. Look, there are groups and competitors that we have that do go en masse and pick up new customers, but they're point solutions, so they're easily replaceable, and that makes it a lot more difficult. If you are a more enterprise solution, it does take more time, but then you become more sticky, and therefore, you stay in for a lot longer. I mentioned this on our AGM call the other day. Pro Medicus, where I was from, 0% churn, but it was slower moving in terms of getting each customer acquisition. But if you have 0% churn, everything just builds on top of each other, and I think that's exactly what we're looking to do with Salix. Yeah, it's slow moving and it can be frustrating, but I think once you're in, you keep your customer happy, you can have long-term deals. Just curious, in your marketing to potential targets, are you able to use other people's data that is out in the public domain, in the broad general sense? Yeah, absolutely. I mean, in the end, plaque is plaque, and you are detecting type of plaque and the volume of plaque. So, I mean, obviously, they will use ours, we will use theirs, and in essence, you are trying to show better patient outcomes through some of those studies. So yeah, whether it is, say, the DECIDE study or PARAMOUNT or the TRANSFORM, whichever it is, our SAPPHIRE, all of those are relevant for the industry to show better indications of one, assessing plaque, but also treating for it as well. So yes, we can, yeah, and we do. Yeah A lot. Yeah. It has helped raising that awareness for the hospital groups as well, because as I mentioned, plaque is sort of a new area of analysis. So, anyone that can raise the awareness, whether it is some of our competitors or not, is a good thing for the industry. Given that there are seven players in total, even if there aren't seven head-to-head competitors, do you think Salix is really defensible against a larger AI medical imaging competitor? Just as an example, like- Well, I mean, hypothetically, if GE or Philips decided to ramp up their investment in this type of imaging analysis. Yeah. No, look, we know those guys really well. They really invest in improving the architecture to the point that is beneficial for doctors. They'll have to effectively start from scratch and scrap everything and then really start the architecture anew. So, at the moment, it's sort of bolting on to what they already have. So, it's become quite a clunky animal, to be honest. So, it's very effective. We've been very effective at replacing them at the five hospitals as well. Their major strength is in metal. I mean, they sell machines. That's where their strength is. That's where their sales teams are incentivized, and they try to wrap around software around that. It doesn't solve the actual problem that hospitals and doctors have at the moment. Yeah. Okay. In regard to the SAPPHIRE study, what's your enrollment up to now, and when do we expect to see some data from that study? Yeah. It's not enrollment as such. It's a retrospective study. We're working with a number of those, the six SAPPHIRE partners, through ethics, and at the moment, some of them are slower. The Brigham, just because they are the Brigham, they're generally a lot slower than most. Some of them are a lot faster. We're in varying stages of where we are getting data from them. That being said, we're still moving that along quite well. We are still commercializing them. I've purposefully, at least for the next few months, just slowed SAPPHIRE down a little bit so I could pull some resources off SAPPHIRE and focus on SCF to make sure that we're getting SCF done and dusted and submitted so we can really just start accelerating from there. Right. You must be really chuffed at winning HonorHealth, non-SAPPHIRE, non-foundation customer. What do you think the significance of that win is for Artrya? I'll give my view. They're a brand new hospital that came to us. We didn't approach them, they heard about us. They are looking to build a center of excellence in imaging to really be a standout and leader in the Arizona area, and also be that flagship imaging center across the U.S. When they came to us, and really understanding what we were doing and told us what they want to do, it was a really good fit because we can help them from an AI reporting, imaging, plaque, flow, and some of the features that we're doing around things like structural as well. They're also looking to bring and buy new scanners, put in leading photon-counting scanners. They're trying to buy two new photon-counting scanners and really ramp the volumes up in Arizona. From our perspective, it's almost a, I won't say it's a blank canvas as such because they're already imaging, but it's a blank canvas in the sense that we can actually help them be state-of-the-art in Arizona and use that as a showcase and a flagship center for us in the U.S. on what a true AI-enabled CCTA platform in a high-volume center with quality scanners looks like. Can we look forward to other inbound non-SAPPHIRE systems Yeah joining over the next 12 months? I'll take the data away, but we are working on a number of different inbounds at the moment. When they land, we'll obviously announce those. Similar to SAPPHIRE, we are working through the remaining five heavily, and we've been through, and have been for quite some time, as well as some of the inbounds. We're working closely with a number of them. Well, that's fantastic. Great overview. Thank you very much. That's all we've got time for, so thanks to both of you for your time and your insights. We'll take a short break and be back with Echo IQ and John Hester.